ID: ALA283122

Max Phase: Preclinical

Molecular Formula: C30H32N6O4S

Molecular Weight: 572.69

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCCOc1ccc(S(=O)(=O)N2CCN(C)CC2)cc1-c1nc(O)c2cc3c(cc2n1)ncn3Cc1ccccc1

Standard InChI:  InChI=1S/C30H32N6O4S/c1-3-15-40-28-10-9-22(41(38,39)36-13-11-34(2)12-14-36)16-24(28)29-32-25-18-26-27(17-23(25)30(37)33-29)35(20-31-26)19-21-7-5-4-6-8-21/h4-10,16-18,20H,3,11-15,19H2,1-2H3,(H,32,33,37)

Standard InChI Key:  SJTYUWYMRLXRKL-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 572.69

Molecular Weight (Monoisotopic): 572.2206

AlogP: 4.13

#Rotatable Bonds: 8

Polar Surface Area: 113.68

Molecular Species: NEUTRAL

HBA: 9

HBD: 1

#RO5 Violations: 1

HBA (Lipinski): 10

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 12.39

CX Basic pKa: 5.99

CX LogP: 5.01

CX LogD: 4.99

Aromatic Rings: 5

Heavy Atoms: 41

QED Weighted: 0.30

Np Likeness Score: -1.58

References

1. Rotella DP, Sun Z, Zhu Y, Krupinski J, Pongrac R, Seliger L, Normandin D, Macor JE..  (2000)  N-3-substituted imidazoquinazolinones: potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction.,  43  (7): [PMID:10753463] [10.1021/jm000081+]

2. Rotella DP, Sun Z, Zhu Y, Krupinski J, Pongrac R, Seliger L, Normandin D, Macor JE..  (2000)  Optimization of substituted N-3-benzylimidazoquinazolinone sulfonamides as potent and selective PDE5 inhibitors.,  43  (26): [PMID:11150175] [10.1021/jm000336j]

Source

Source(1):

• Scientific Literature